Abbott HIV drug ‘could prevent cervical cancer’

Kaletra, the Abbott anti-HIV drug, could be used to prevent cervical cancer, according to a new report.

Scientists from the University of Manchester found that small doses of the drug, known by its generic name as lopinavir, have the ability to selectively destroy cervical cancer cells containing the HPV virus, which is a major risk factor for the development of cervical cancer.

If human trials are successful, new formulations of Kaletra could mean more women avoid surgery for the treatment of early cervical cancer, the BBC has reported.

Dr Ian Hampson, group leader for the study, stated: “It is very exciting to find such a significant new use for this HIV drug which is already licensed and FDA-approved for oral administration.”

“A non surgical therapy will have significant advantages – better preservation of obstetric function, the potential for use in resource poor settings such as underdeveloped countries and it may appeal more to women than surgery,” he added.

The study investigators say they are researching methods to deliver Kaletra to cervical areas before embarking on clinical trials, to be led by Professor Henry C Kitchener.

He said that before regulatory approval can be considered, the effectiveness of the new treatment would need to be established.

Abbott claims that Kaletra is one of the world’s most prescribed protease inhibitors. It is one of the company’s best selling drugs.

In July, the European Commission approved a new Kaletra formulation allowing patients to take their medication four times a day, rather than the standard six.

© Adfero Ltd